Dergiler / Hacettepe Journal of Biology and Chemistry / 2026 / Volume: 49 Issue: 3

DNAJC25 as a tumor suppressor candidate gene in breast cancer

Tolga Acun(Zonguldak Bülent Ecevit University)0000-0001-7636-1783
Sayfa
—
Yayın Tarihi
2021-05-17
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Functional studies are essential to reveal its role in breast carcinogenesis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:DNAJC25 gene is a member of the HSP40 (DNAJ) family, and it was suggested as a tumor suppressor gene in hepatocellular carcinoma.
📊
Temel Bulgular & Veri:The aim of this study was to analyze the expression, genetic/epigenetic alterations, and prognostic value of the DNAJC25 gene in breast cancer.
💡
Sonuç & Katkı:Functional studies are essential to reveal its role in breast carcinogenesis.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:DNAJC25 · HSP40 · biomarker

Abstract

DNAJC25 gene is a member of the HSP40 (DNAJ) family, and it was suggested as a tumor suppressor gene in hepatocellular carcinoma. The aim of this study was to analyze the expression, genetic/epigenetic alterations, and prognostic value of the DNAJC25 gene in breast cancer. DNAJC25 transcript levels are upregulated in BT-20 and ZR-75-1 cell lines and downregulated in MDA-MB-231 cell line compared to the non-tumorigenic mammary epithelial cell line (MCF 10A) (P< 0.05). According to UALCAN in-silico tool, clinical breast cancer samples show significantly reduced levels of DNAJC25 mRNA levels relative to the normal samples (P=1.47e-02). The Kaplan–Meier plotter tool shows that high DNAJC25 expression is favorable for post-progression survival in breast cancer (P=0.0035). Point mutations or copy number variations of DNAJC25 are uncommon in clinical breast cancer samples. Combined bisulfite restriction analysis (COBRA) results showed that DNAJC25 promoter is not methylated in breast cell lines. Promoter hypomethylation was also observed in normal and tumor clinical samples (Beta-value < 0.25). In conclusion, DNAJC25 is suggested as a tumor suppressor candidate having limited biomarker potential in breast cancer. Functional studies are essential to reveal its role in breast carcinogenesis.

🔖

Bu Makaleye Atıf Yap

Acun, T. (2021). DNAJC25 as a tumor suppressor candidate gene in breast cancer. Hacettepe Journal of Biology and Chemistry, Volume: 49 Issue: 3. https://doi.org/10.15671/hjbc.725263

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Prof. Dr. Uygar Halis TAZEBAY ([email protected]
  2. Prof. Dr. K. Can AKÇALI ([email protected] )